JPRN-C000000170已完成2 期
A phase II randomized study of DP(Docetaxel+Cisplatin),DJ(Docetaxel+Carboplatin),and TJ(Paclitaxel+Carboplatin) in patients with advanced and recurrent endometrial carcinoma - Evaluation of Taxane and Platinum combinations in patients with advanced and recurrent endometrial carcinoma
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •-Patients with sarcomatous element -Active infections -Serious complications (heart disease, interstitial lung disease, uncontrolled hypertension, diabetes mellitus and tendency to bleeding) -Massive pleural effusion or ascites -Neuropathy grade 2 or more; edema grade 2 or more (NCI-CTC) -Active concomitant malignancy -Hypersensitivity to Polysorbate 80 or Cremophor EL -Patients judged inappropriate for this study by the physicians
研究者
相似试验
招募中
不适用
Phase I/II study of bi-weekly docetaxel and cisplatin plus S-1 (bi-weekly DCS) as first-line therapy for advanced esophageal cancer.Esophageal cancerJPRN-UMIN000032257The University of Tokyo50
招募中
1 期
Phase I/II study of bi-weekly DCS as first-line therapy for advanced esophageal cancer.Esophageal cancerJPRN-jRCTs031180376Seto Yasuyuki38
未知
2 期
A phase II study of combination Docetaxel, Cisplatin, and S-1 as neoadjuvant chemotherapy for advanced gastric cancer.advanced gastric cancerJPRN-UMIN000000801Dept. of Internal Medicine(4)30
进行中（未招募）
不适用
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - DOCOX GASTRIC (Docetaxel-Oxaliplatin in Gastric Cancer)Metastatic or local recurrent gastric cancer previously untreated with chemotherapy for advance disease.MedDRA version: 8.1Classification code 10017758EUCTR2005-005464-92-HUSanofi-aventis groupe270
进行中（未招募）
不适用
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - GATE (GAstric cancer study with Taxotere-Eloxatin-based regimens)Metastatic or local recurrent gastric cancer previously untreated with chemotherapy for advance disease.MedDRA version: 8.1Classification code 10017758EUCTR2005-005464-92-BESanofi-aventis groupe270